BioPharmSignal logoBioPharmSignal

Biotech News

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Recursion (RXRX)RecursionPartnership

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027

Related news

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

RXRXRecursion2026-08-05 10:30 EST

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

CHRSCoherus BioSciences, Inc.2026-06-23 18:00 EST

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

ALVOAlvotech2026-10-06 20:37 EST

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

MDXGMiMedx2026-10-28 20:01 EST

MIMEDX Announces $25 Million Patent License Agreement

APGEApogee Therapeutics2026-05-27 10:31 EST

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

ENTXEntera Bio2026-06-22 12:30 EST

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

STTKShattuck Labs2026-06-05 20:05 EST

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

ENTXEntera Bio2026-05-28 12:50 EST

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

View all latest news

Recursion

AI-Native Drug Discovery Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental...

Recent company news

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

RXRXRecursion2026-11-02 21:25 EST

New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

RXRXRecursion2026-11-02 21:05 EST

Recursion Appoints Fred Hassan as Chair of the Board

RXRXRecursion2026-10-26 20:05 EST

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

RXRXRecursion2026-10-15 12:45 EST

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Stock data

Close
3.50 USD
Market cap
1.92B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States